Sai Parenterals Limited has announced that its board meeting will take place on Saturday, May 23, 2026. The meeting will be convened at the company's registered office to discuss and approve several key financial agendas.

Agenda for the Meeting

The primary focus of the board meeting will be to consider the unaudited financial results for the quarter and nine months ended December 31, 2025. Additionally, the board will review the Limited Review Report for the quarter ended December 31, 2025.

Audited Results for FY26

In a significant move, the board will also consider the audited financial results for the quarter and year ended March 31, 2026. This includes the review of the Audit Report for the financial year ending March 31, 2026, for both standalone and consolidated entities.

Key Details

The intimation was sent to the BSE Limited and NSE Limited on May 19, 2026, pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was signed by Anil Kumar Karusala, Executive Director of Sai Parenterals Limited.

Sai Parenterals Limited, a pharmaceutical research and manufacturing company, has filed its Monitoring Agency Report for the quarter ended March 31, 2026, pursuant to Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, read with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report was prepared by India Ratings & Research Private Limited and submitted to the stock exchanges on May 12, 2026.

IPO Issue Overview

The company conducted its Initial Public Offer during March 2026, with the issue period running from March 24, 2026 to March 27, 2026, and an anchor issue date of March 23, 2026. The IPO comprised a fresh issue as well as an offer for sale component. The key issue details are summarised below:

The promoters of the company are Anil Kumar Karusala, Vijitha Gorrepati, and Karusala Aruna.

Nil Utilization Reported for the Quarter

For the quarter ended March 31, 2026, the Monitoring Agency confirmed nil utilization of IPO proceeds across all stated objects. The entire fresh issue amount of INR 2,850.00 Million remains unutilized and is currently held in an Axis Bank escrow account (A/c: 926020003760575). No earnings, maturity date, or return on investment has been recorded for the funds during this period.

The utilization status against each object of the issue is presented below:

No Deviation from Offer Document Objects

Based on the Management Representation and the Statutory Auditor Certificate dated May 8, 2026, issued by R Kabra & Co. LLP, Chartered Accountants (FRN – 104502W/W100721), the Monitoring Agency confirmed no deviation from the objects stated in the Offer Document. The means of finance for the disclosed objects have not changed, and no material deviations requiring shareholder approval were identified.

All six primary expenditure objects, along with issue-related expenses, are reported as ongoing with a target completion timeline of Fiscal 2027, consistent with the disclosures in the Offer Document. No delay in implementation has been recorded, and no unfavorable events affecting the viability of the objects were reported.

Deployment of Unutilized Proceeds

The full IPO proceeds of INR 2,850.00 Million continue to be held in the Escrow Axis Bank account pending deployment. There was nil utilization under the General Corporate Purposes head during the current quarter as well.

The report was signed by Shrikant Dev, Company Secretary at India Ratings & Research Private Limited, on May 11, 2026, and submitted to the exchanges by Anil Kumar Karusala, Managing Director of Sai Parenterals Limited, on May 12, 2026.